These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 24229770)

  • 1. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
    Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
    Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients.
    Tahara N; Nitta Y; Bekki M; Tahara A; Maeda-Ogata S; Sugiyama Y; Honda A; Igata S; Nakamura T; Sun J; Kurata S; Fujimoto K; Abe T; Matsui T; Yamagishi SI; Fukumoto Y
    J Nucl Cardiol; 2020 Aug; 27(4):1352-1364. PubMed ID: 31407236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Liraglutide on Arterial Inflammation Assessed as [
    Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
    Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE).
    Koyama H; Tanaka S; Monden M; Shoji T; Morioka T; Fukumoto S; Mori K; Emoto M; Shoji T; Fukui M; Fujii H; Nishizawa Y; Inaba M
    Atherosclerosis; 2014 Jun; 234(2):329-34. PubMed ID: 24727234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging.
    Vucic E; Dickson SD; Calcagno C; Rudd JH; Moshier E; Hayashi K; Mounessa JS; Roytman M; Moon MJ; Lin J; Tsimikas S; Fisher EA; Nicolay K; Fuster V; Fayad ZA
    JACC Cardiovasc Imaging; 2011 Oct; 4(10):1100-9. PubMed ID: 21999870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Nesto R; Kupfer S; Perez A; Jure H; De Larochellière R; Staniloae CS; Mavromatis K; Saw J; Hu B; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1561-73. PubMed ID: 18378631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events.
    Figueroa AL; Abdelbaky A; Truong QA; Corsini E; MacNabb MH; Lavender ZR; Lawler MA; Grinspoon SK; Brady TJ; Nasir K; Hoffmann U; Tawakol A
    JACC Cardiovasc Imaging; 2013 Dec; 6(12):1250-9. PubMed ID: 24269261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial.
    Boczar KE; Shin S; deKemp RA; Dowlatshahi D; Tavoosi A; Wiefels C; Liu P; Lochnan H; MacPherson PA; Chong AY; Torres C; Leung E; Tawakol A; Ahmadi A; Garrard L; Lefebvre C; Kelly C; MacPhee P; Tilokee E; Raggi P; Wells GA; Beanlands R
    BMJ Open; 2023 Nov; 13(11):e074463. PubMed ID: 37949621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.
    Duivenvoorden R; Mani V; Woodward M; Kallend D; Suchankova G; Fuster V; Rudd JHF; Tawakol A; Farkouh ME; Fayad ZA
    JACC Cardiovasc Imaging; 2013 Oct; 6(10):1087-1094. PubMed ID: 24135322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.
    Kim TN; Kim S; Yang SJ; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Circ Cardiovasc Imaging; 2010 Mar; 3(2):142-8. PubMed ID: 20061516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.
    Kataoka Y; Shao M; Wolski K; Uno K; Puri R; Tuzcu EM; Nissen SE; Nicholls SJ
    Eur J Prev Cardiol; 2013 Apr; 20(2):209-17. PubMed ID: 22345692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
    Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
    JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.
    Hong SJ; Kim ST; Kim TJ; Kim EO; Ahn CM; Park JH; Kim JS; Lee KM; Lim DS
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2655-65. PubMed ID: 21030718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study.
    Singh P; Emami H; Subramanian S; Maurovich-Horvat P; Marincheva-Savcheva G; Medina HM; Abdelbaky A; Alon A; Shankar SS; Rudd JH; Fayad ZA; Hoffmann U; Tawakol A
    Circ Cardiovasc Imaging; 2016 Dec; 9(12):e004195. PubMed ID: 27956407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.